Open Access

Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma

  • Yutao Diao1, 2,
  • Hao Li3,
  • Huiqing Li2Email author,
  • Yingzhi Zhou4,
  • Qing Ma2,
  • Yan Wang1 and
  • Dong Li5
Contributed equally
Lipids in Health and Disease20098:48

https://doi.org/10.1186/1476-511X-8-48

Received: 28 September 2009

Accepted: 29 October 2009

Published: 29 October 2009

Abstract

Background

The aim of the study was to evaluate the association of immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein (oxLDL-lgG) and oxLDL-lgM with the progression of esophageal squamous cell carcinoma (ESSC).

Methods

Residents from Feicheng, China aged 40 to 69 years were screened for esophageal lesions in a screening program conducted during the period of January 2008 to December 2006. There were 33 controls with normal esophageal squamous epithelium cells, 37 patients with basal cell hyperplasia, 47 with esophageal squamous cell dysplasia, and 43 with ESCC. All the participants were diagnosed by biopsy and histopathological examination. Adiponectin, oxidized low-density lipoprotein (oxLDL), autoantibodies against oxLDL (oxLDL-ab), OxLDL-lgG, and OxLDL-lgM were determined by enzyme linked immunosorbent assay (ELISA). Total cholesterol, High-density lipoprotein (HDL), triglyceride, serum albumin, and blood pressure were co-estimated. Analysis of covariance for lipid levels was used to control the influence of covariates.

Results

The level of oxLDL-lgM increased gradually along with esophageal carcinoma progression. The oxLDL-lgM levels in the ESCC group were the highest after possible covariates were controlled. Binary logistic regression showed that oxLDL-lgM had a positive correlation with the development of esophageal carcinoma, while oxLDL and oxLDL-ab had a negative correlation with ESSC. No significant association between the levels of oxLDL-lgG and adiponectin and the different stages of ESSC was observed.

Conclusion

The present study shows that the decreased oxLDL and oxLDL-ab and the elevated oxLDL-lgM serum levels may relate to the development and progression of ESSC.

Background

Conflicting data have been reported on the association between low serum cholesterol levels and the risk for cancer mortality. Some observational studies show that low serum cholesterol is associated with an increased risk of cancer mortality [14], but some failed to establish a connection [58].

A meta-analysis of 18 cohort studies showed a significantly increased risk of total cancer death in men (but not in women) with total cholesterol concentrations less than 160 mg/dL(4.15 mmol/L) compared with those with levels at 160-199 mg/dL (4.15-5.16 mmol/L) [9].

There may be a causal link between low cholesterol and cancer. But it is possible that the associations between low blood cholesterol concentrations and risks of cancer are the consequences of confounding factors [3, 4]. In addition, it is also possible that the associations follow a cause-and-effect relationship, possibly the preclinical cancer effect on cholesterol levels [1012]. For instance, mortality from liver and colon cancer is significantly associated with a very low cholesterol level without any evidence of a preclinical cholesterol-lowering effect [13].

Although the mechanism is unclear, this phenomenon indicates that blood lipid levels are related to the development and progression of tumors. However, expression levels of serum cholesterol may not be the unique representative of the lipid markers.

The significance of lipid and its novel constituents such as adiponectin, immunoglobulin G and M types of autoantibodies to oxidized low-density lipoprotein (oxLDL-lgG and oxLDL-lgM) has been previously established in relation to cardiovascular disease [14, 15]. Oxidized LDL, as an autoantigen, plays a crucial role in atherogenic lesion formation [16, 17]. Serum oxLDL as well as the autoantibodies against it (oxLDL-ab) may be considered as biomarkers of lipid peroxidation [18]. There are two antibody isotypes to oxLDL, namely, the IgG and IgM autoantibodies. Although still controversial, overall evidence supports the notion that IgG autoantibodies to OxLDL are associated with pro-atherogenic properties and IgM autoantibodies to OxLDL with anti-atherogenic properties [1921].

Meanwhile, studies also showed that adiponectin, oxLDL-lgG, and oxLDL-lgM may play a role in various types of malignancies [15]. Petridou, et al. studied the relationship between adiponectin and childhood myeloblastic leukemia [22], while Wang, et al. proposed that oxLDL autoantibody might be related to esophageal cancer [23]. Furthermore, it has been found in animal models that a high level of lipid peroxidation is closely associated with carcinogenesis [24, 25].

It can be assumed that lipid and its novel constituents(oxLDL-ab, oxLDL-lgG and oxLDL-lgM) may also be associated with different stages in carcinogenesis proceeding. Pathological and epidemiological studies suggest that the malignant transformation of human esophageal mucosa is a progressive process that starts from normal epithelium to basal cell hyperplasia, followed by dysplasia, or carcinoma in situ, and finally to invasive esophageal squamous cell carcinoma (ESCC). Dysplasia, out of the 4 progressive stages is considered as an important precancerous lesion of esophageal cancer [2628].

In this context, we carried out a program for the screening of esophageal lesions by endoscopic staining with 1.2% iodine solution in Feicheng, China between January 2004 and December 2006. Through the program, we obtained samples of 4 groups respectively having normal epithelium, basal cell hyperplasia, dysplasia, or carcinoma in situ, and ESCC. The foundation of these samples pressed us to establish the relationship of the serum levels of lipid-related constituents to these different lesions and carcinoma of the esophagus, especially the levels of oxLDL-lgG or/and oxLDL-lgM to the different stages in the progression of ESSC.

Methods

Study subjects

Between January 2004 and December 2006, we screened all the residents aged 40 to 69 in Feicheng, China, who agreed to participate in the program. We excluded those with liver diseases, diabetes, or cardiovascular diseases including coronary heart disease, angina pectoris, myocardial infarction, cardiac arrhythmia, and heart failure diagnosed by general medical check up, electrocardiogram, and abdomen supersonic inspection. All participants took part in the endoscopic staining with 1.2% iodine solution. Biopsies were taken from a non-staining area of the mucosa, and the samples underwent two separate pathologic evaluations carried out by two pathologists. Based on the examinations, the subjects were divided into four groups: the control group with normal esophageal squamous epithelium cells, the basal cell hyperplasia group, the esophageal squamous cell dysplasia group, and the ESCC group. The subjects in this study were randomly selected from the four groups. There were 33 subjects with normal esophageal squamous epithelium cells in the control group; 37 patients had basal cell hyperplasia, 47 had esophageal squamous cell dysplasia, and 43 had ESCC. Informed consent was obtained from all the subjects. The study protocol was approved by the local ethics committee.

Measurements

An epidemiologic survey of the characteristics of the subjects such as name, gender, age, and smoking and drinking habits was conducted using a questionnaire. The body weight and height of each subject were measured, and the body mass index (BMI) was calculated as weight in kilograms divided by height in square meters. Blood pressure was measured by mercury sphygmomanometer. Hypertension was defined as having systolic pressure (SBP) ≥ 140 mmHg and/or diastolic pressure (DBP) ≥ 90 mmHg, or those who were already undergoing medications for hypertension.

Blood Sampling and Biochemical Analysis

Venous blood samples were taken in the morning after an overnight fast of at least 12 hr. Plasma and serum were separated according to the different requirements. The specimens were kept frozen at -40°C until assayed. High density lipoprotein (HDL), total cholesterol (TC), and triglyceride (TG) levels were determined by enzymatic techniques. Low density lipoprotein (LDL) was calculated by the Friedewald formula [LDL = TC - HDL - TG/5]. Serum albumin was determined by the bromocresol green method. All the assays were performed under the instructions supplied by the corresponding manufacturers.

Determination of serum ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM

An enzyme-linked immunosorbent assay(ELISA) for ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM was performed with ADP, oxLDL, oxLDL-ab, oxLDL-lgG and oxLDL-lgM ELISA kits purchased from ADL (Adliteram Diagnostic Laboratories Inc., USA). According to the manufacturer's instructions, using coated microtitration strips 96 wells, plasma was diluted 1:1 and incubated at room temperature for 1 hr in plates precoated with ADP, oxLDL, oxLDL-ab, oxLDL-lgG, or oxLDL-lgM, respectively. After washing 3 times, the plates were incubated with horseradish peroxidase (HRP) at room temperature for 30 min. After the removal of unbound conjugates by washing 3 times, tetramethylbenzidine (TMB) was added to the wells as a chromogenic substrate and incubated at room temperature for 10 min in the dark. Color development was stopped with stopping solution, and the absorbency was measured at 450 nm within 30 min. ADP, oxLDL, oxLDL-ab, oxLDL-lgG, or oxLDL-lgM titers were calculated by constructing a standard curve using the standards included in the respective kits. The concentrations of ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM in the samples were quantified in biomedical units as defined by the manufacturer. The intra-assay and interassay reproducibility (indicated by coefficients of variation) of the assay were 6, 5, 7, 6, and 10 percent, respectively.

Statistical analysis

All statistical analyses were conducted using SPSS 15.0. The baseline characteristics were presented for quantitative data as mean (SD). The comparison in the four groups was performed using the Student's t test. The qualitative data were tested by the Chi-square test. The correlation between variables was tested using the Pearson correlation test depending on the distribution of the data. A general linear model analysis was used to control the influence of covariates when comparing the concentrations of ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM among the four groups. Multinomial logistic regression was applied to analyze the influential factors. Probability was significant at a level of ≤ 0.05.

Results

Characteristics of subjects

The clinical and biochemical characteristics of the studied population are shown in Table 1. The variables of age, albumin, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein(LDL), oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM were significantly different among the four groups. There were no significant differences in the other variables.
Table 1

Characteristics of the Subjects

variables

Control group

Basal cell hyperplasia

Dysplasia group

ESSC group

F/x2

p

Age, years

49 ± 8

53 ± 8

56 ± 7

58 ± 7

10.286

0.000*

Sex, M/F

18/15

24/13

28/19

28/15

1.155

0.764

Hypertension, Y/N

18/15

20/17

18/29

21/22

2.893

0.408

BMI, kg/m2

22.90 ± 2.72

22.93 ± 2.90

22.06 ± 2.60

21.73 ± 3.31

1.728

0.164

SBP, mmHg

132 ± 26

132 ± 19

131 ± 20

127 ± 17

0.549

0.649

DBP, mmHg

86 ± 14

85 ± 12

82 ± 12

78 ± 14

2.325

0.077

Smokers, Y/N

15/18

17/20

24/23

24/19

1.119

0.773

Drinkers, Y/N

15/18

24/13

24/23

23/20

2.890

0.409

Albumin, g/L

38 ± 3

44 ± 8

40 ± 6

38 ± 8

8.161

0.000*

TC, mmol/L

3.45 ± 1.09

3.63 ± 0.83

3.62 ± 0.80

2.54 ± 0.96

13.684

0.000*

TG, mmol/L

0.61 ± 0.43

0.68 ± 0.46

0.57 ± 0.40

0.50 ± 0.32

1.481

0.222

LDL, mmol/L

0.12 ± 0.33

0.08 ± 0.27

0.09 ± 0.28

0.23 ± 0.15

11.439

0.000*

HDL, mmol/L

0.77 ± 0.22

0.91 ± 0.22

0.85 ± 0.21

0.67 ± 0.24

8.667

0.000*

ADP, ng/L

10.27 ± 10.98

11.18 ± 13.10

14.33 ± 13.38

12.98 ± 11.79

0.850

0.469

oxLDL, ng/L

33.66 ± 11.54

27.40 ± 10.33

30.27 ± 11.83

23.94 ± 10.72

5.264

0.002*

oxLDL-ab, U/ml

38.33 ± 26.44

38.97 ± 21.38

32.52 ± 12.87

26.59 ± 7.88

4.210

0.007*

oxLDL-lgG, ng/ml

12.54 ± 4.67

18.14 ± 10.47

16.56 ± 8.42

10.23 ± 6.78

8.453

0.000*

oxLDL-lgM, ng/ml

20.56 ± 5.99

23.27 ± 6.17

24.63 ± 6.35

26.60 ± 5.88

6.402

0.000*

* p < 0.05; Abbreviations: ESSC, esophageal squamous cell carcinoma; MBI, body mass index; SBP, 0 systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; ADP, adiponectin; oxLDL, oxidized low-density lipoprotein; oxLDL-lgG, immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein; oxLDL-lgM, immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein.

Comparison of serum levels of ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM among the four groups

A general linear model analysis showed that there were significant differences in the estimated marginal means of plasma oxLDL and oxLDL-lgM among the four groups. However, no significant differences were observed for ADP, oxLDL-ab and oxLDL-lgG after controlling the confounding variables i.e. age, TC, HDL, LDL, and albumin (Table 2). The results of the linear-by-linear association analysis showed that the blood serum levels of oxLDL and oxLDL-ab were decreased. However, the blood serum level of oxLDL-lgM increased with the histological spectrum of disease from normal to early invasive squamous cell carcinoma of the esophagus (Figure 1).
Table 2

Estimated Marginal Means and UNIANOVA Test of Apinectin, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM in Four Groupsa

 

ADP

oxLDL

oxLDL-ab

oxLDL-lgG

oxLDL-lgM

ESSC group

11.699 ± 2.715

25.436 ± 1.951

28.123 ± 3.124

13.378 ± 1.214

26.519 ± 1.073

Dysplasia group

13.980 ± 1.867

30.130 ± 1.675

32.101 ± 2.681

15.645 ± 1.065

24.380 ± 0.921

Basal cell hyperplasia group

11.903 ± 2.202

26.629 ± 1.976

37.367 ± 3.164

15.553 ± 1.257

22.989 ± 1.087

Control group

11.614 ± 2.363

32.790 ± 2.120

38.742 ± 3.395

12.656 ± 1.349

21.329 ± 1.166

F test

0.332

2.739

2.098

1.445

3.503

P

0.802

0.045

0.103

0.232

0.017

Trend testb

1.518

9.421

10.412

2.789

17.137

P

0.218

0.002

0.001

0.095

0.000

Abbreviations: TC, total cholesterol; TG, triglyceride; ADP, adiponectin; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; oxLDL, oxidized low-density lipoprotein; oxLDL-lgG, immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein; oxLDL-lgM, immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein.

a Means (SE) for estimated marginal means; Covariates appearing in the model are evaluated at the following values: TG = 3.2961, LDL = 2.2317, HDL = 0.7992, Albumin = 40.2234, age = 54.55.

b Linear --by --linear association test.

Figure 1

Mean concentrations of serum biochemical indicators in group. Mean concentrations of serum biochemical indicators in groups of ESSC (A), dysplasia (B), basal cell hyperplasia (C), and normal control (D). Adp, HDL, LDL, oxLDL, oxLDL-ab, oxLDL-IgG, oxLDL-IgM, TC, and TG respectively represent adiponectin, high-density lipoprotein, low-density lipoprotein, oxidized low-density lipoprotein, total antibodies to oxidized low density lipoprotein, oxidized low-density lipoprotein IgG, oxidized low-density lipoprotein IgM, total cholesterol, and total triglyceride.

Association of ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM with multistage development of esophageal carcinoma

As shown in Table 3, the Odds ratio (OR) of ADP, oxLDL, oxLDL-ab, oxLDL-lgG and oxLDL-lgM were associated with the different stages in the development of esophageal carcinoma (basal cell hyperplasia, dysplasia and early invasive cancer) after adjusted for age, albumin, TC, HDL and LDL.
Table 3

Multinomial Logistic Analysis for the Multistage Development of Esophageal Carcinoma

 

Unadjusted OR & 95%CL

Adjusted OR & 95%CL*

variables

ESSC

dysplasia

Basal cell hyperplasia

ESSC

dysplasia

Basal cell hyperplasia

ADP

1.02(0.98-1.06)

1.03(0.99-1.07)

1.01(0.97-1.05)

1.02(0.97-1.06)

1.03(0.99-1.07)

1.01(0.96-1.05)

oxLDL

0.92(0.88-0.94)

0.98(0.94-1.01)

0.96(0.92-1.00)

0.94(0.89-0.99)

0.97(0.93-1.01)

0.95(0.91-0.99)

oxLDL-ab

0.93(0.88-0.97)

0.98(0.96-1.01)

1.00(0.98-1.02)

0.96(0.91-1.00)

0.98(0.95-1.01)

1.00(0.98-1.02)

oxLDL-lgG

0.94(0.87-1.01)

1.07(1.01-1.14)

1.09(1.03-1.16)

1.03(0.94-1.13)

1.07(0.99-1.16)

1.07(0.99-1.15)

oxLDL-lgM

1.21(1.10-1.33)

1.15(1.05-1.27)

1.11(1.01-1.22)

1.18(1.06-1.31)

1.11(1.01-1.23)

1.08(0.98-1.20)

Abbreviations: TC, total cholesterol; TG, triglyceride; ADP, adiponectin; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; oxLDL, oxidized low-density lipoprotein; oxLDL-lgG, immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein; oxLDL-lgM, immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein.

*:adjusted for age, albumin, TC, HDL, and LDL.

It is also indicated that the ORs for oxLDL-lgM were positively linked with the ESSC and dysplasia group. However, ORs for oxLDL and oxLDL-ab were negatively associated with the two groups, even if the ORs did not reached statistics significantly levels in dysplasia group.

Discussion

In the present study, there was a significantly lower serum level of TC and HDL-c. Moreover, there were significantly higher serum levels of LDL-c in the ESSC group than those in the control group, which is similar to those previously found in the literature [15, 10].

Plasma adiponectin levels were found to be lower in patients with many cancers, especially in upper gastric cancers, compared with those in the normal controls. It is inversely correlated with tumor size, depth of invasion, and tumor TNM stage, suggesting a potential role of adiponectin in the progression of gastric cancer [29]. There was no similar information for esophageal carcinoma. In the present study, we did not find plasma adiponectin levels to be related to the multistage development of esophageal cancer.

The predominant isotype of oxLDL antibodies isolated either from serum (free antibodies) or from precipitated soluble immune complexes (antigen-associated antibodies) is IgG, which is of the subclasses 1 and 3 [30, 31]. A positive correlation between the levels of oxLDL-lgG antibodies and the different endpoints considered as evidence of atherosclerotic vascular disease has been reported by many studies [32, 33]. In addition, the protective role of IgM oxLDL antibodies has been proposed in human cardiovascular diseases [25, 34]. However, other studies have failed to support these findings [3537].

Recent research works show that the antibody against oxLDL serum levels in patients with hepatocellular carcinoma [38] and squamous cell carcinoma of the esophagus [17] is lower than that in the normal controls. However, the isotypes of oxLDL-lgG and oxLDL-lgM were not separately detected in these reports.

The main finding of the present study is the descending trends of plasma oxLDL, oxLDL-ab, and oxLDL-lgG levels and the elevated trends of plasma oxLDL-lgM levels along with the series of histological spectrum of disease from normal to early invasive squamous cell carcinoma of the esophagus.

In recent years, there has been a growing body of evidence that states the excessive lipid peroxidation products including oxLDL and anti-oxLDL autoantibodies, which are reflected in the indicators of oxidative stress in vivo, may play a key role in cancer development [39, 40]. Lipid peroxidation metabolites damage DNA and can seriously inhibit DNA repair capacity through their direct interaction with repair proteins [41]. Furthermore, they influence the intracellular redox equilibrium, affecting several crucial signal transduction pathways [42]. The oxLDL, shown either in vivo or in vitro, has a cytotoxic effect against endothelial cells and smooth muscle cells of the arterial wall, as well as a chemotactic activity for circulating monocytes [21]. Low serum levels of the oxLDL antibody can lead to uncontrolled cell proliferation and to the reduction of apoptosis, contributing to the induction of carcinogenesis. oxLDL increases the activity of C protein kinase (PKC), which is a serin-treonin kinase that acts on the cytoplasmatic transduction of the mytogenic signal, induced from GF [43]. The PKC exerts its action supporting the activity of P21 ras protein involved in the pathogenesis of many humans tumors [44]. oxLDL is also able to induce the production and delivery of other growth factors (GF) such as that derived from platelets (PDGF), probably through interleukin 1 and TNF-β. It has been demonstrated that PDGF, codified from c-sys oncogenes, seems to be involved in the uncontrolled growth of many tumors [45]. The anti-oxLDL autoantibodies may be activated through all these different ways to induce the development and progression of esophageal cancer.

In this study, all subjects were diagnosed by histopathology, which ruled out the possibility of the misclassification error. In the experimental determination of the indicators, we used less than 10 percent of the coefficient of variation as quality control. In order to avoid the occurrence of collinearity, a covariance analysis was used in the analysis. The variance inflation factor(VIF) of ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM were 0.232, 0.880, 0.910, 0.867, and 0.984, respectively. Therefore, the main results of this study were neither biased nor by chance.

In the present study, we found that the descending levels of oxLDL and oxLDL-ab may negatively related to the different stages of the development of esophageal cancer while the elevated levels of oxLDL-lgM has a positive potence, which is contrary in the case of their relations to cardiovascular and cerebrovascular diseases revealed in previous literature.

However, the isotype antibodies against oxLDL serum levels in cancer cannot be defined in universal terms. Furthermore, large clinical sample studies are required in order to elucidate whether oxLDL as well as oxLDL antibodies play a causative or merely consequential role in the cancer process, and to designate a novel strategy for cancer prevention and therapy.

Conclusion

This study shows that the decreasing oxLDL and oxLDL-ab negatively relate to the different stages of the development of esophageal squamous cell carcinoma while the elevated oxLDL-lgM serum levels may positively relate to the development and progression of ESSC. This conclusion may be helpful for cancer prevention and therapy.

Notes

Abbreviations

TC: 

total cholesterol

TG: 

triglyceride

ADP: 

adiponectin

HDL: 

High-density lipoprotein

LDL: 

Low-density lipoprotein

oxLDL: 

oxidized low-density lipoprotein

oxLDL-lgG: 

immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein

oxLDL-lgM: 

immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein

ESCC: 

esophageal squamous cell carcinoma

oxLDL-ab: 

antibodies to oxidized low density lipoprotein

Declarations

Acknowledgements

This study were supported by the Projects of National Natural Science Foundation of China (No.30571601 & No.30600258), the doctor fund projects of 2006 in Shandong Province (No. 2006BS03061) and the special fund for innovative projects in the post-doctoral funding of 2007 (No. 200,702,034) in Shandong Province, China.

Authors’ Affiliations

(1)
College of Public Health, Shandong University
(2)
Institute of Basic Medicine of Shandong Academy of Medical Sciences
(3)
Department of Hematology, Tumor Center of Qilu Hospital, Shandong University
(4)
College of Economics, Shandong University
(5)
People's Hospital

References

  1. Schuit AJ, Van Dijk CEM, Dekker JM, Schouten EG, Kok FJ: Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am J Epidemiol. 1993, 137: 966-976.PubMedGoogle Scholar
  2. Wannamethee G, Shaper AG, Whincup PH, Walker M: Low serum total cholesterol concentrations and mortality in middle aged British men. BMJ. 1995, 311: 409-413.PubMed CentralView ArticlePubMedGoogle Scholar
  3. D'Agostino RB, Belanger AJ, Kannel WB, Higgins M: Role of smoking in the U-shaped relation of cholesterol to mortality in men. The Framingham Study. Am J Epidemiol. 1995, 141: 822-827.PubMedGoogle Scholar
  4. Eichholzer M, Stähelin HB, Gutzwiller F, Lüdin E, Bernasconi F: Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr. 2000, 71: 569-574.PubMedGoogle Scholar
  5. Iribarren C, Reed DM, Burchfield CM, Dwyer JH: Serum total cholesterol and mortality. JAMA. 1995, 273: 1926-1932. 10.1001/jama.273.24.1926View ArticlePubMedGoogle Scholar
  6. Smith GD, Shipley MJ, Marmot MG, Rose G: Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA. 1992, 267: 70-76. 10.1001/jama.267.1.70View ArticlePubMedGoogle Scholar
  7. Dyer AR, Stamler J, Paul O, Shekelle RB, Schoenberger JA, Berkson DM, Lepper M, Collette P, Shekelle S, Lindberg HA: Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. J Chronic Dis. 1981, 34: 249-260. 10.1016/0021-9681(81)90030-8View ArticlePubMedGoogle Scholar
  8. Baptiste MS, Nasca PC, Doyle JT, Rothenberg RR, MacCubbin PA, Mettlin C, Metzger BB, Carlton KA: Cholesterol and cancer in a population of male civil service workers. Int J Epidemiol. 1992, 21: 16-22. 10.1093/ije/21.1.16View ArticlePubMedGoogle Scholar
  9. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B: Report of the conference on low blood cholesterol: mortality associations. Circulation. 1992, 86: 1046-1060.View ArticlePubMedGoogle Scholar
  10. Pekkanen J, Nissinen A, Punsar S, Karvonen MJ: Short- and long-term association of serum cholesterol with mortality: the 25-year follow-up of the Finnish cohorts of the Seven Countries Study. Am J Epidemiol. 1992, 135: 1251-1258.PubMedGoogle Scholar
  11. Wannamethee G, Shaper AG, Whincup PH, Walker M: Low serum total cholesterol concentrations and mortality in middle-aged British men. BMJ. 1995, 311: 409-413.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Sharp SJ, Pocock SJ: Time trends in serum cholesterol before cancer death. Epidemiology. 1997, 8: 132-136. 10.1097/00001648-199703000-00002View ArticlePubMedGoogle Scholar
  13. Song YM, Sung JH, Kim JS: Which Cholesterol Level Is Related to the Lowest Mortality in a opulation with Low Mean Cholesterol Level: A 6.4-Year Follow-up Study of 482, 472 Korean Men. Am J Epidemiol. 2000, 151: 739-747.View ArticlePubMedGoogle Scholar
  14. Virella G, Carter RE, Saad A, Crosswell EG, Game BA: DCCT/EDIC Study Group and Maria F. Lopes-Virella. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clinical Immunology. 2008, 127: 394-400. 10.1016/j.clim.2008.02.005PubMed CentralView ArticlePubMedGoogle Scholar
  15. Bar D, Williams CJ, Neuwirth AK, Mantzoros CS: Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007, 86 (suppl): 858s-866s.Google Scholar
  16. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996, 37: 45-53.PubMedGoogle Scholar
  17. Uchida K: 4-hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003, 42: 318-343. 10.1016/S0163-7827(03)00014-6View ArticlePubMedGoogle Scholar
  18. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002, 22: 1649-1654. 10.1161/01.ATV.0000033829.14012.18View ArticlePubMedGoogle Scholar
  19. Gounopoulos P, Merki E, Hansen LF, Choi SH, Tsimikas S: Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 2007, 55: 821-837.PubMedGoogle Scholar
  20. Ohashi R, Mu H, Yao Q, Chen C: Atherosclerosis: immunopathogenesis and immunotherapy. Med Sci Monit. 2004, 10: 255-260.Google Scholar
  21. Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S: Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation. 2003, 108: 2107-2112. 10.1161/01.CIR.0000092891.55157.A7View ArticlePubMedGoogle Scholar
  22. Petridou E, Mantzoros CS, Dessypris N, Trichopoulos D: Adiponectin in relation to childhood myeloblastic leukaemia. British J Cancer. 2006, 94: 156-160. 10.1038/sj.bjc.6602896.View ArticleGoogle Scholar
  23. Wang Y, Li H, Diao Y, Li H, Zhang Y, Yin C, Cui Y, Ma Q, Fang X, Zhou Y, Yang Y: Relationship between oxidized LDL antibodies and different stages of esophageal carcinoma. Arch Med Res. 2008, 39: 760-767. 10.1016/j.arcmed.2008.08.002View ArticlePubMedGoogle Scholar
  24. Chung FL, Nath RG, Ocando J, Nishikawa A, Zhang L: Deoxyguanosine adducts of t-4-hydroxy-2-nonenal are endogenous DNA lesions in rodents and humans: detection and potential sources. Cancer Res. 2000, 60: 1507-1511.PubMedGoogle Scholar
  25. ánchez-Pérez Y, Carrasco-Legleu C, García-Cuellar C, Pérez-Carreón J, Hernández-García S, Salcido-Neyoy M, Alemán-Lazarini L, Villa-Treviño S: Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett. 2005, 217: 25-32. 10.1016/j.canlet.2004.07.019View ArticleGoogle Scholar
  26. Yang CS: Research on esophageal cancer in China: a review. Cancer Res. 1980, 40: 2633-2644.PubMedGoogle Scholar
  27. Qiu SL, Yang GR: Precursor lesions of esophageal cancer in high-risk populations in Henan Province, China. Cancer. 1988, 62: 551-557. 10.1002/1097-0142(19880801)62:3<551::AID-CNCR2820620319>3.0.CO;2-YView ArticlePubMedGoogle Scholar
  28. Yang GR, Oiu SL: Endoscopic surveys in high-risk populations for esophageal cancer in China with special reference to precursors of esophageal cancer. Endoscopy. 1987, 19: 91-95. 10.1055/s-2007-1018250View ArticleGoogle Scholar
  29. Kelesidis I, Kelesidis T, Mantzoros CS: Adiponectin and cancer: a systematic review. British Journal of Cancer. 2006, 94: 1221-1225. 10.1038/sj.bjc.6603051PubMed CentralView ArticlePubMedGoogle Scholar
  30. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M: Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol. 2000, 95: 135-144. 10.1006/clim.2000.4857View ArticlePubMedGoogle Scholar
  31. Virella G, Lopes-Virella MF: Lipoprotein autoantibodies: measurement and significance. Clin Diag Lab Immunol. 2003, 10: 499-505.Google Scholar
  32. Erkkilä AT, Närvänen O, Lehto S, Uusitupa MIJ, Ylä-Herttuala S: Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscl. Thromb Vasc Biol. 2000, 20: 204-209.View ArticleGoogle Scholar
  33. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF: OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006, 47: 1975-1983. 10.1194/jlr.M600064-JLR200View ArticlePubMedGoogle Scholar
  34. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG: High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004, 110: 1406-1412. 10.1161/01.CIR.0000141728.23033.B5View ArticlePubMedGoogle Scholar
  35. Boullier A, Hamon M, Walters-Laporte E, Martin-Nizart F, Mackereel R, Fruchart JC, Bertrand M, Duriez P: Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta. 1995, 238: 1-10.View ArticlePubMedGoogle Scholar
  36. Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G: Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscl Thromb Vasc Biol. 2001, 21: 269-274.View ArticlePubMedGoogle Scholar
  37. Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, Shah PK, Nilsson J, Nilsson J: Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke. 2007, 38: 1495-1500. 10.1161/STROKEAHA.106.474577View ArticlePubMedGoogle Scholar
  38. Ozer Nk, Boscoboinik D, Azzi A: New roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis. Biochem Mol Biol Intern. 1995, 35: 117-124.Google Scholar
  39. Guyton KZ, Kensler TW: Oxidative mechanisms in carcinogenesis. Br Med Bull. 1993, 49: 481-483.Google Scholar
  40. Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen species; role in inflammatory disease and progression to cancer. Biochem J. 1996, 313: 17-19.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Brown NS, Bicknell R: Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3: 323-327. 10.1186/bcr315PubMed CentralView ArticlePubMedGoogle Scholar
  42. Motta M, Pistone G, Franzone AM, Romeo MA, Di Mauro S, Giugno I, Ruello P, Malaguarnera M, Malaguarnera M: Antibodies against oxLDL serum levels in patients with hepatocellular carcinoma. Panminerva Med. 2003, 45: 69-73.PubMedGoogle Scholar
  43. Kelly K, Cochran BH, Stiles CD, Leder P: Cell specific regulation in normal and neoplastic cells. Adv Cancer Res. 1990, 56: 1-48.Google Scholar
  44. Downward J, Graves JD, Warne PH: Stimulation of P21 (MD30) ras upon T-cell activation. Nature. 1990, 346: 719-723. 10.1038/346719a0View ArticlePubMedGoogle Scholar
  45. Oberhammaer F, Burch W, Parzefall W, Breit P, Erber E, Stadler M, Schulte-Hermann R: Effect of transforming growth factor β on cell death of cultured rat hepatocytes. Cancer Res. 1991, 51: 2478-2485.Google Scholar

Copyright

© Diao et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement